Top Markets
#1 Helium Helium +54.36%
#2 Seeker Seeker +47.01%
#3 Pons Pons +36.71%
#4 UnifAI Network UnifAI Network +26.90%
#5 Tensor Tensor +23.04%
#6 Bounce Bounce +18.99%
#7 TENDIES TENDIES +18.92%
#8 DAPPOS DAPPOS +18.17%
#9 Zylo Ecosystem Zylo Ecosystem +17.03%
#10 Songbird Songbird +15.70%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY
Rank in Stocks #11086
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines designed to significantly improve patients' lives. The company employs cutting-edge platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation. Central to their technological approach is the zinc finger protein (ZFP) platform, which provides both ZFP nucleases for precise DNA sequence modification (allowing for gene addition or knockout) and ZFP transcription factors for upregulating or downregulating gene expression. Their development pipeline includes SB-525, currently in a Phase III AFFINE clinical trial for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 trials for sickle cell disease. Additionally, Sangamo is advancing TX200, a chimeric antigen receptor for HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502 for synucleinopathies, which include Parkinson's disease and other neuromuscular disorders. The company maintains extensive collaborative and strategic partnerships with prominent organizations such as Biogen MA, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., and F. Hoffmann-La Roche Ltd. Originally incorporated in 1995 as Sangamo BioSciences, Inc., the company adopted its current name in January 2017 and is headquartered in Brisbane, California.
Share Price
$5.21
Last synced: 2022-08-11
Market Cap
$745.49M
Change (1 day)
0.15%
Change (1 year)
0.00%
Country
US
Trade Sangamo Therapeutics, Inc. (GBY)

Category

Healthcare
Number of shares outstanding for Sangamo Therapeutics, Inc. (GBY)
Number of shares outstanding as of August 2026: 0
According to Sangamo Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Sangamo Therapeutics, Inc. (GBY) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH